Financial

News

AstraZeneca plans new US R&D hub as revenues rocket

AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven by COVID-19 and oncology

News

Merck makes $3.2bn from COVID-19 drug Lagevrio in Q1

Orders for Merck & Co's oral antiviral for COVID-19 helped to swell the drugmaker's first quarter revenues by a massive 50%, although underlying growth was also strong.

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer plans €25bn R&D spend, fuelled by Jardiance

Boehringer Ingelheim says it is planning to invest a hefty €25 billion ($27 billion) in its pipeline over the next five years, as it reinvests healthy sales revenue from Eli Lilly-partnered

News

Bluebird sheds a third of its workforce to cut costs

Gene therapy specialist bluebird bio has said 30% of its workforce will lose their jobs, in a bid to conserve cash as it tried to get its lead programmes over the finish line.

News

Eisai hands off responsibility for Aduhelm to Biogen

Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer's therapy Aduhelm, handing over full responsibility to its US counterpart.

News

bluebird says future uncertain as delays to gene therapies b...

As bluebird bio struggles to get its gene therapies over the finishing line, the company says its financial position raises "substantial doubt" about its ability to continue as a going conc

AstraZeneca plans new US R&D hub as revenues rocket

Merck makes $3.2bn from COVID-19 drug Lagevrio in Q1

Boehringer plans €25bn R&D spend, fuelled by Jardiance

Bluebird sheds a third of its workforce to cut costs

Eisai hands off responsibility for Aduhelm to Biogen

bluebird says future uncertain as delays to gene therapies b...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Financial

Editor's Picks